Empfehlung
6,0
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | Alkermes plc. |
|---|---|
| Ticker | ALKS |
| CIK | 0001520262 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Alkermes plc. |
Status
| Zuletzt geprüft | 2026-03-20 22:23:17.840412 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2,034 | 29.76 | -60,531.84 | -26,7% | |
| 2026-03-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 29.72 | -267,485.40 | -118,0% | |
| 2026-03-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 29.72 | -267,485.40 | -118,0% | |
| 2026-03-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 29.72 | -267,485.40 | -118,0% | |
| 2026-03-02 | Nichols Christian Todd | Officer, SVP, Chief Commercial Officer | Open Market Sale | -6,000 | 30.00 | -180,000.00 | -79,4% | |
| 2026-03-02 | Gaffin David Joseph | Officer, EVP, CLO, Alkermes, Inc. | Open Market Sale | -2,034 | 29.29 | -59,575.86 | -26,3% | |
| 2026-03-02 | Parisi Samuel Joseph | Officer, VP, Finance (Interim PAO) | Open Market Sale | -6,890 | 29.29 | -201,808.10 | -89,0% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 33.54 | -134,160.00 | -59,2% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -29,087 | 34.34 | -998,795.22 | -440,5% | |
| 2026-02-02 | Cooke Shane | Director | Open Market Sale | -32,113 | 34.78 | -1,116,877.29 | -492,6% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 34.24 | -171,224.50 | -75,5% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 33.54 | -134,160.00 | -59,2% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 34.24 | -171,224.50 | -75,5% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 33.54 | -134,160.00 | -59,2% | |
| 2026-02-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 34.24 | -171,224.50 | -75,5% | |
| 2026-01-08 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 30.00 | -150,005.00 | -66,2% | |
| 2026-01-08 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 30.00 | -150,005.00 | -66,2% | |
| 2026-01-08 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -5,000 | 30.00 | -150,005.00 | -66,2% | |
| 2026-01-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 28.00 | -112,000.00 | -49,4% | |
| 2026-01-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 28.00 | -112,000.00 | -49,4% | |
| 2026-01-02 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 28.00 | -112,000.00 | -49,4% | |
| 2025-12-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -3,748 | 30.00 | -112,447.12 | -49,6% | |
| 2025-12-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -3,748 | 30.00 | -112,447.12 | -49,6% | |
| 2025-12-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -3,748 | 30.00 | -112,447.12 | -49,6% | |
| 2025-12-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 29.30 | -117,200.00 | -51,7% | |
| 2025-12-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 29.30 | -117,200.00 | -51,7% | |
| 2025-12-01 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -4,000 | 29.30 | -117,200.00 | -51,7% | |
| 2025-11-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 30.38 | -273,441.60 | -120,6% | |
| 2025-11-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 30.38 | -273,441.60 | -120,6% | |
| 2025-11-03 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 30.38 | -273,441.60 | -120,6% | |
| 2025-10-15 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 31.53 | -283,776.30 | -125,1% | |
| 2025-10-15 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 31.53 | -283,776.30 | -125,1% | |
| 2025-10-15 | Hopkinson Craig C. | Officer, EVP R&D, Chief Medical Officer | Open Market Sale | -9,000 | 31.53 | -283,776.30 | -125,1% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.